Increase in serum alkaline phosphatase (S-ALP) in chronic myelocytic leukemia--sign of drug-induced cholestasis?
In four patients with chronic myelocytic leukemia, a solitary rise in serum alkaline phosphatase (S-ALP) was noted 2--12 months prior to death. All patients had received busulphan (Myleran) therapy for longer than 12 months (total dosage 1.0--2.4 g). It is suggested that the increase in S-alp was due to a cholestatic liver damage, possible secondary to the busulphan treatment.
D000328:Adult; D000469:Alkaline Phosphatase / Q000097:blood*; D002066:Busulfan / Q000009:adverse effects* / Q000627:therapeutic use; D002779:Cholestasis / Q000139:chemically induced* / Q000201:enzymology; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000201:enzymology*; D008297:Male; D013997:Time Factors
D000469:Alkaline Phosphatase; D002066:Busulfan